These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24641673)

  • 1. V-antigen homologs in pathogenic gram-negative bacteria.
    Sawa T; Katoh H; Yasumoto H
    Microbiol Immunol; 2014 May; 58(5):267-85. PubMed ID: 24641673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
    Sawa T; Ito E; Nguyen VH; Haight M
    Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiological survey of serum titers from adults against various Gram-negative bacterial V-antigens.
    Kinoshita M; Shimizu M; Akiyama K; Kato H; Moriyama K; Sawa T
    PLoS One; 2020; 15(3):e0220924. PubMed ID: 32155175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.
    Frank DW; Vallis A; Wiener-Kronish JP; Roy-Burman A; Spack EG; Mullaney BP; Megdoud M; Marks JD; Fritz R; Sawa T
    J Infect Dis; 2002 Jul; 186(1):64-73. PubMed ID: 12089663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytolytic toxins from gram-negative bacteria.
    Ludwig A
    Microbiologia; 1996 Jun; 12(2):281-96. PubMed ID: 8767711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and immunogenicity of a potential multivalent type III secretion system-based protein vaccine.
    Markham AP; Barrett BS; Esfandiary R; Picking WL; Picking WD; Joshi SB; Middaugh CR
    J Pharm Sci; 2010 Nov; 99(11):4497-509. PubMed ID: 20845449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further characterization of a type III secretion system (T3SS) and of a new effector protein from a clinical isolate of Aeromonas hydrophila--part I.
    Sha J; Wang SF; Suarez G; Sierra JC; Fadl AA; Erova TE; Foltz SM; Khajanchi BK; Silver A; Graf J; Schein CH; Chopra AK
    Microb Pathog; 2007 Oct; 43(4):127-46. PubMed ID: 17644303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury.
    Sawa T; Yahr TL; Ohara M; Kurahashi K; Gropper MA; Wiener-Kronish JP; Frank DW
    Nat Med; 1999 Apr; 5(4):392-8. PubMed ID: 10202927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV.
    Daniel C; Sebbane F; Poiret S; Goudercourt D; Dewulf J; Mullet C; Simonet M; Pot B
    Vaccine; 2009 Feb; 27(8):1141-4. PubMed ID: 19135495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic homology of endotoxin with a coliform mastitis vaccine strain, Escherichia coli O111:B4 (J5).
    Tyler JW; Spears H; Nelson R
    J Dairy Sci; 1992 Jul; 75(7):1821-5. PubMed ID: 1500577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigens of the type-three secretion system of Aeromonas salmonicida subsp. salmonicida prevent protective immunity in rainbow trout.
    Bergh PV; Burr SE; Benedicenti O; von Siebenthal B; Frey J; Wahli T
    Vaccine; 2013 Oct; 31(45):5256-61. PubMed ID: 24012573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yersinia outer protein E, YopE. A versatile type III effector molecule for cytosolic targeting of heterologous antigens by attenuated Salmonella.
    Rüssmann H
    Adv Exp Med Biol; 2003; 529():407-13. PubMed ID: 12756799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K; Wiener-Kronish JP; Sawa T
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis.
    Weeks S; Hill J; Friedlander A; Welkos S
    Microb Pathog; 2002 May; 32(5):227-37. PubMed ID: 12071679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel multivalent vaccine based on secretary antigen-delivery induces protective immunity against Vibrio anguillarum and Aeromonas hydrophila.
    Zhou L; Wang X; Liu Q; Wang Q; Zhao Y; Zhang Y
    J Biotechnol; 2010 Mar; 146(1-2):25-30. PubMed ID: 20026209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury.
    Wang Q; Li H; Zhou J; Zhong M; Zhu D; Feng N; Liu F; Bai C; Song Y
    Respir Physiol Neurobiol; 2014 Mar; 193():21-8. PubMed ID: 24418353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple whole bacterial antigens in polyvalent vaccine may result in inhibition of specific responses in rainbow trout (Oncorhynchus mykiss).
    Nikoskelainen S; Verho S; Järvinen S; Madetoja J; Wiklund T; Lilius EM
    Fish Shellfish Immunol; 2007 Mar; 22(3):206-17. PubMed ID: 16849036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type III secretion gets an LcrV tip.
    Mota LJ
    Trends Microbiol; 2006 May; 14(5):197-200. PubMed ID: 16564172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes.
    Goure J; Pastor A; Faudry E; Chabert J; Dessen A; Attree I
    Infect Immun; 2004 Aug; 72(8):4741-50. PubMed ID: 15271936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles.
    Mueller CA; Broz P; Müller SA; Ringler P; Erne-Brand F; Sorg I; Kuhn M; Engel A; Cornelis GR
    Science; 2005 Oct; 310(5748):674-6. PubMed ID: 16254184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.